# One and Two Doses of Oxfendazole Versus a Schedule of Two Doses of Triclabendazole in Chronic Fascioliasis

> **NCT06367361** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Universidad Peruana Cayetano Heredia** · enrollment: 336 (estimated)

## Conditions studied

- Fascioliasis

## Interventions

- **DRUG:** Oxfendazole
- **DRUG:** Triclabendazole

## Key facts

- **NCT ID:** NCT06367361
- **Lead sponsor:** Universidad Peruana Cayetano Heredia
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-15
- **Primary completion:** 2029-03-15
- **Final completion:** 2029-03-15
- **Target enrollment:** 336 (ESTIMATED)
- **Last updated:** 2026-05-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06367361

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06367361, "One and Two Doses of Oxfendazole Versus a Schedule of Two Doses of Triclabendazole in Chronic Fascioliasis". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06367361. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*